MYC Is a Major Determinant of Mitotic Cell Fate

Cancer Cell

Volumn 28, Issue 1, 2015, Pages 129-140

  Topham, Caroline ^a   Tighe, Anthony ^a   Ly, Peter ^b   Bennett, Ailsa ^a   Sloss, Olivia ^a   Nelson, Louisa ^a   Ridgway, RachelA ^c   Huels, David ^c   Littler, Samantha ^a   Schandl, Claudia ^a   Sun, Ying ^b   Bechi, Beatrice ^a   Procter, DavidJ ^a   Sansom, OwenJ ^c   Cleveland, DonW ^b   Taylor, StephenS ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^c BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BH3 PROTEIN; MYC PROTEIN; PACLITAXEL; PROTEIN BCL XL; ANTIMITOTIC AGENT; BCL2L1 PROTEIN, HUMAN; C22ORF29 PROTEIN, HUMAN; EARLY GROWTH RESPONSE FACTOR 1; EGR1 PROTEIN, HUMAN; MYC PROTEIN, HUMAN; MYC PROTEIN, MOUSE; PROTEIN BCL 2; PROTEIN BCL X;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CANCER; CELL FATE; CONTROLLED STUDY; GENE EXPRESSION; INTESTINE CRYPT; MITOSIS; MITOSIS INHIBITION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; ANIMAL; BREAST TUMOR; COLON TUMOR; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; MOLECULAR GENETICS; NEOPLASM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIMITOTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; BREAST NEOPLASMS; CELL LINE, TUMOR; COLONIC NEOPLASMS; EARLY GROWTH RESPONSE PROTEIN 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE; MITOSIS; MOLECULAR SEQUENCE DATA; NEOPLASMS; OVARIAN NEOPLASMS; PACLITAXEL; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 84937401224     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.06.001     Document Type: Article

References (68)

1. A'Hern R.P., Jamal-Hanjani M., Szász A.M., Johnston S.R., Reis-Filho J.S., Roylance R., Swanton C. Taxane benefit in breast cancer-a role for grade and chromosomal stability. Nat. Rev. Clin. Oncol. 2013, 10:357-364.
2. Bah N., Maillet L., Ryan J., Dubreil S., Gautier F., Letai A., Juin P., Barillé-Nion S. Bcl-xL controls a switch between cell death modes during mitotic arrest. Cell Death Dis. 2014, 5:e1291.
3. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6910-6924.
4. Berns K., Horlings H.M., Hennessy B.T., Madiredjo M., Hijmans E.M., Beelen K., Linn S.C., Gonzalez-Angulo A.M., Stemke-Hale K., Hauptmann M., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12:395-402.
5. Boone D.N., Qi Y., Li Z., Hann S.R. Egr1 mediates p53-independent c-Myc-induced apoptosis via a noncanonical ARF-dependent transcriptional mechanism. Proc. Natl. Acad. Sci. USA 2011, 108:632-637.
6. Brito D.A., Rieder C.L. Mitotic checkpoint slippage in humans occurs via cyclin B destruction in the presence of an active checkpoint. Curr. Biol. 2006, 16:1194-1200.
7. Campone M., Noël B., Couriaud C., Grau M., Guillemin Y., Gautier F., Gouraud W., Charbonnel C., Campion L., Jézéquel P., et al. c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol. Cancer 2011, 10:110.
8. Conacci-Sorrell M., McFerrin L., Eisenman R.N. An overview of MYC and its interactome. Cold Spring Harb Perspect Med 2014, 4:a014357.
9. den Hollander J., Rimpi S., Doherty J.R., Rudelius M., Buck A., Hoellein A., Kremer M., Graf N., Scheerer M., Hall M.A., et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. Blood 2010, 116:1498-1505.
10. Díaz-Martínez L.A., Karamysheva Z.N., Warrington R., Li B., Wei S., Xie X.J., Roth M.G., Yu H. Genome-wide siRNA screen reveals coupling between mitotic apoptosis and adaptation. EMBO J. 2014, 33:1960-1976.
11. Dumontet C., Jordan M.A. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat. Rev. Drug Discov. 2010, 9:790-803.
12. Egle A., Harris A.W., Bouillet P., Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc. Natl. Acad. Sci. USA 2004, 101:6164-6169.
13. Eichhorn J.M., Alford S.E., Sakurikar N., Chambers T.C. Molecular analysis of functional redundancy among anti-apoptotic Bcl-2 proteins and its role in cancer cell survival. Exp. Cell Res. 2014, 322:415-424.
14. Eick D., Bornkamm G.W. Transcriptional arrest within the first exon is a fast control mechanism in c-myc gene expression. Nucleic Acids Res. 1986, 14:8331-8346.
15. Eilers M., Eisenman R.N. Myc's broad reach. Genes Dev. 2008, 22:2755-2766.
16. Eischen C.M., Woo D., Roussel M.F., Cleveland J.L. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol. Cell. Biol. 2001, 21:5063-5070.
17. Filippakopoulos P., Qi J., Picaud S., Shen Y., Smith W.B., Fedorov O., Morse E.M., Keates T., Hickman T.T., Felletar I., et al. Selective inhibition of BET bromodomains. Nature 2010, 468:1067-1073.
18. Garnett M.J., Edelman E.J., Heidorn S.J., Greenman C.D., Dastur A., Lau K.W., Greninger P., Thompson I.R., Luo X., Soares J., et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012, 483:570-575.
19. Gascoigne K.E., Taylor S.S. Cancer cells display profound intra-and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008, 14:111-122.
20. Gascoigne K.E., Taylor S.S. How do anti-mitotic drugs kill cancer cells?. J.Cell Sci. 2009, 122:2579-2585.
21. Glück S., Ross J.S., Royce M., McKenna E.F., Perou C.M., Avisar E., Wu L. TP53 genomics predict higher clinical and pathologic tumor response in operable early-stage breast cancer treated with docetaxel-capecitabine± trastuzumab. Breast Cancer Res. Treat. 2012, 132:781-791.
22. Goga A., Yang D., Tward A.D., Morgan D.O., Bishop J.M. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC. Nat. Med. 2007, 13:820-827.
23. Hann S.R. MYC cofactors: molecular switches controlling diverse biological outcomes. Cold Spring Harb Perspect Med 2014, 4:a014399.
24. Harley M.E., Allan L.A., Sanderson H.S., Clarke P.R. Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J. 2010, 29:2407-2420.
25. Hayashi M.T., Cesare A.J., Fitzpatrick J.A.J., Lazzerini-Denchi E., Karlseder J. A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest. Nat. Struct. Mol. Biol. 2012, 19:387-394.
26. Hemann M.T., Bric A., Teruya-Feldstein J., Herbst A., Nilsson J.A., Cordon-Cardo C., Cleveland J.L., Tansey W.P., Lowe S.W. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005, 436:807-811.
27. Horiuchi D., Kusdra L., Huskey N.E., Chandriani S., Lenburg M.E., Gonzalez-Angulo A.M., Creasman K.J., Bazarov A.V., Smyth J.W., Davis S.E., et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J.Exp. Med. 2012, 209:679-696.
28. Huang H.C., Mitchison T.J., Shi J. Stochastic competition between mechanistically independent slippage and death pathways determines cell fate during mitotic arrest. PLoS ONE 2010, 5:e15724.
29. Iaccarino I., Hancock D., Evan G., Downward J. c-Myc induces cytochrome c release in Rat1 fibroblasts by increasing outer mitochondrial membrane permeability in a Bid-dependent manner. Cell Death Differ. 2003, 10:599-608.
30. Iba T., Kigawa J., Kanamori Y., Itamochi H., Oishi T., Simada M., Uegaki K., Naniwa J., Terakawa N. Expression of the c-myc gene as a predictor of chemotherapy response and a prognostic factor in patients with ovarian cancer. Cancer Sci. 2004, 95:418-423.
31. Janssen A., van der Burg M., Szuhai K., Kops G.J., Medema R.H. Chromosome segregation errors as a cause of DNA damage and structural chromosome aberrations. Science 2011, 333:1895-1898.
32. Keen N., Taylor S. Mitotic drivers-inhibitors of the Aurora B Kinase. Cancer Metastasis Rev. 2009, 28:185-195.
33. Kessler J.D., Kahle K.T., Sun T., Meerbrey K.L., Schlabach M.R., Schmitt E.M., Skinner S.O., Xu Q., Li M.Z., Hartman Z.C., et al. A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science 2012, 335:348-353.
34. Komlodi-Pasztor E., Sackett D.L., Fojo A.T. Inhibitors targeting mitosis: tales of how great drugs against a promising target were brought down by a flawed rationale. Clin. Cancer Res. 2012, 18:51-63.
35. Lara-Gonzalez P., Westhorpe F.G., Taylor S.S. The spindle assembly checkpoint. Curr. Biol. 2012, 22:R966-R980.
36. Lessene G., Czabotar P.E., Sleebs B.E., Zobel K., Lowes K.N., Adams J.M., Baell J.B., Colman P.M., Deshayes K., Fairbrother W.J., et al. Structure-guided design of a selective BCL-X(L) inhibitor. Nat. Chem. Biol. 2013, 9:390-397.
37. Li Q., Dang C.V. c-Myc overexpression uncouples DNA replication from mitosis. Mol. Cell. Biol. 1999, 19:5339-5351.
38. Lowe S.W., Cepero E., Evan G. Intrinsic tumour suppression. Nature 2004, 432:307-315.
39. McKeown M.R., Bradner J.E. Therapeutic strategies to inhibit MYC. Cold Spring Harb Perspect Med 2014, 4:a014266.
40. McMahon S.B. MYC and the control of apoptosis. Cold Spring Harb Perspect Med 2014, 4:a014407.
41. Minn A.J., Boise L.H., Thompson C.B. Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. Genes Dev. 1996, 10:2621-2631.
42. Mitchison T.J. The proliferation rate paradox in antimitotic chemotherapy. Mol. Biol. Cell 2012, 23:1-6.
43. Murray S., Briasoulis E., Linardou H., Bafaloukos D., Papadimitriou C. Taxane resistance in breast cancer: mechanisms, predictive biomarkers and circumvention strategies. Cancer Treat. Rev. 2012, 38:890-903.
44. Muthalagu N., Junttila M.R., Wiese K.E., Wolf E., Morton J., Bauer B., Evan G.I., Eilers M., Murphy D.J. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep. 2014, 8:1347-1353.
45. Nagase H., Fukuyama H., Tanaka M., Kawane K., Nagata S. Mutually regulated expression of caspase-activated DNase and its inhibitor for apoptotic DNA fragmentation. Cell Death Differ. 2003, 10:142-143.
46. Nikiforov M.A., Riblett M., Tang W.H., Gratchouck V., Zhuang D., Fernandez Y., Verhaegen M., Varambally S., Chinnaiyan A.M., Jakubowiak A.J., Soengas M.S. Tumor cell-selective regulation of NOXA by c-MYC in response to proteasome inhibition. Proc. Natl. Acad. Sci. USA 2007, 104:19488-19493.
47. Orth J.D., Loewer A., Lahav G., Mitchison T.J. Prolonged mitotic arrest triggers partial activation of apoptosis, resulting in DNA damage and p53 induction. Mol. Biol. Cell 2012, 23:567-576.
48. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002, 109:321-334.
49. Phesse T.J., Myant K.B., Cole A.M., Ridgway R.A., Pearson H., Muncan V., van den Brink G.R., Vousden K.H., Sears R., Vassilev L.T., et al. Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage invivo. Cell Death Differ. 2014, 21:956-966.
50. Radulescu S., Ridgway R.A., Appleton P., Kroboth K., Patel S., Woodgett J., Taylor S., Nathke I.S., Sansom O.J. Defining the role of APC in the mitotic spindle checkpoint invivo: APC-deficient cells are resistant to Taxol. Oncogene 2010, 29:6418-6427.
51. Rieder C.L., Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 2004, 7:637-651.
52. Shi J., Zhou Y., Huang H.C., Mitchison T.J. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL. Cancer Res. 2011, 71:4518-4526.
53. Silk A.D., Zasadil L.M., Holland A.J., Vitre B., Cleveland D.W., Weaver B.A. Chromosome missegregation rate predicts whether aneuploidy will promote or suppress tumors. Proc. Natl. Acad. Sci. USA 2013, 110:E4134-E4141.
54. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N.Engl. J. Med. 2001, 344:783-792.
55. Sodir N.M., Evan G.I. Finding cancer's weakest link. Oncotarget 2011, 2:1307-1313.
56. Soucek L., Jucker R., Panacchia L., Ricordy R., Tatò F., Nasi S. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 2002, 62:3507-3510.
57. Tang Y.C., Amon A. Gene copy-number alterations: a cost-benefit analysis. Cell 2013, 152:394-405.
58. Taylor S.S., McKeon F. Kinetochore localization of murine Bub1 is required for normal mitotic timing and checkpoint response to spindle damage. Cell 1997, 89:727-735.
59. Thompson S.L., Compton D.A. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J.Cell Biol. 2010, 188:369-381.
60. Topham C.H., Taylor S.S. Mitosis and apoptosis: how is the balance set?. Curr. Opin. Cell Biol. 2013, 25:780-785.
61. Upreti M., Galitovskaya E.N., Chu R., Tackett A.J., Terrano D.T., Granell S., Chambers T.C. Identification of the major phosphorylation site in Bcl-xL induced by microtubule inhibitors and analysis of its functional significance. J.Biol. Chem. 2008, 283:35517-35525.
62. Weaver B.A. How Taxol/paclitaxel kills cancer cells. Mol. Biol. Cell 2014, 25:2677-2681.
63. Wiese K.E., Walz S., von Eyss B., Wolf E., Athineos D., Sansom O., Eilers M. The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med 2013, 3:a014290.
64. Wirth M., Stojanovic N., Christian J., Paul M.C., Stauber R.H., Schmid R.M., Häcker G., Krämer O.H., Saur D., Schneider G. MYC and EGR1 synergize to trigger tumor cell death by controlling NOXA and BIM transcription upon treatment with the proteasome inhibitor bortezomib. Nucleic Acids Res. 2014, 42:10433-10447.
65. Wolf E., Lin C.Y., Eilers M., Levens D.L. Taming of the beast: shaping Myc-dependent amplification. Trends Cell Biol. 2015, 25:241-248.
66. Wong M., Tan N., Zha J., Peale F.V., Yue P., Fairbrother W.J., Belmont L.D. Navitoclax (ABT-263) reduces Bcl-x(L)-mediated chemoresistance in ovarian cancer models. Mol. Cancer Ther. 2012, 11:1026-1035.
67. Yang D., Liu H., Goga A., Kim S., Yuneva M., Bishop J.M. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc. Natl. Acad. Sci. USA 2010, 107:13836-13841.
68. Zasadil L.M., Andersen K.A., Yeum D., Rocque G.B., Wilke L.G., Tevaarwerk A.J., Raines R.T., Burkard M.E., Weaver B.A. Cytotoxicity of paclitaxel in breast cancer is due to chromosome missegregation on multipolar spindles. Sci. Transl. Med. 2014, 6:229-243.